Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1925 of 3284 entries
View as:

A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.

Phase: N/A Priority: Normal
NCT ID: NCT05644600 Org: User:
Start: 05/26/23 End: 07/17/23 Due: 07/17/24

Dapagliflozin Post Marketing Surveillance in HF and CKD

Phase: N/A Priority: Normal
NCT ID: NCT05134701 Org: User:
Start: 03/10/22 End: 05/20/24 Due: 05/20/25

A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients

Phase: N/A Priority: Normal
NCT ID: NCT02279407 Org: User:
Start: 01/31/15 End: 12/31/15 Due: 12/31/16

Topical Roflumilast in Adults With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT01856764 Org: User:
Start: 06/30/13 End: 03/31/14 Due: 03/31/15

A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT03976869 Org: User:
Start: 07/24/19 End: 07/09/20 Due: 07/09/21

HF Prevalence and Evolution of HF in DM II Patients at High Risk

Phase: N/A Priority: Normal
NCT ID: NCT04482283 Org: User:
Start: 07/20/20 End: 11/21/24 Due: 11/21/25

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT04492722 Org: User:
Start: 10/01/20 End: 09/06/22 Due: 09/06/23

A Bioavailability Study Comparing 3 Different AZD1981 Tablets

Phase: N/A Priority: Normal
NCT ID: NCT01311635 Org: User:
Start: 04/30/11 End: 06/30/11 Due: 06/30/12

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00389389 Org: User:
Start: 09/30/06 End: 10/31/08 Due: 10/31/09

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase: N/A Priority: Normal
NCT ID: NCT03330847 Org: User:
Start: 03/07/18 End: 12/10/25 Due: 12/10/26

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06502379 Org: User:
Start: 08/02/24 End: 10/27/25 Due: 10/27/26

Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01355354 Org: User:
Start: 06/30/11 End: 09/30/11 Due: 09/30/12

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT06610526 Org: User:
Start: 08/23/24 End: 04/27/27 Due: 04/27/28

Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00695539 Org: User:
Start: 12/31/07 End: 12/31/08 Due: 12/31/09

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Phase: N/A Priority: Normal
NCT ID: NCT02094261 Org: User:
Start: 05/20/14 End: 11/07/23 Due: 11/07/24

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

Phase: N/A Priority: Normal
NCT ID: NCT00206102 Org: User:
Start: 09/30/03 End: 10/31/08 Due: 10/31/09

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT06692738 Org: User:
Start: 11/18/24 End: 10/08/29 Due: 10/08/30

DOuBLED - Doubling Outcomes by Lung Cancer Early Diagnosis

Phase: N/A Priority: Normal
NCT ID: NCT05091437 Org: User:
Start: 12/30/21 End: 11/30/24 Due: 11/30/25

Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

Phase: N/A Priority: Normal
NCT ID: NCT04068168 Org: User:
Start: 01/30/20 End: 12/27/24 Due: 12/27/25

FAITH - Factor XA Inhibitor-Related InTracranial Haemorrhage

Phase: N/A Priority: Normal
NCT ID: NCT06420011 Org: User:
Start: 07/08/24 End: 11/01/24 Due: 11/01/25

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

Phase: N/A Priority: Normal
NCT ID: NCT00338130 Org: User:
Start: 07/31/06 End: 07/31/13 Due: 07/31/14

Phase I Study in Patients With Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT00496028 Org: User:
Start: 03/31/07 End: 03/31/10 Due: 03/31/11

QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance

Phase: N/A Priority: Normal
NCT ID: NCT05160974 Org: User:
Start: 12/30/21 End: 04/01/24 Due: 04/01/25

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551

Phase: N/A Priority: Normal
NCT ID: NCT00860353 Org: User:
Start: 02/28/09 End: 05/31/09 Due: 05/31/10

Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00234442 Org: User:
Start: 07/31/04 End: 02/28/06 Due: 02/28/07